精神疾病与新冠疫苗接种后抗体应答:西班牙加泰罗尼亚前瞻性人群研究
在西班牙加泰罗尼亚939名已接种新冠疫苗的成年人中,评估十年内精神疾病诊断及精神药物处方与接种后IgG和IgA抗体水平的关联。心境障碍与较低的IgG RBD抗体水平相关(变化百分比=-26.37,95%CI -42.00至-6.54),其他诊断组(主要为失眠和尼古丁依赖)亦与较低IgG RBD水平相关(变化百分比=-21.53,95%CI -35.38至-4.71)。
要点
- 心境障碍与接种后较低的IgG RBD抗体水平相关(变化百分比=-26.37,95%CI -42.00至-6.54)。
- 其他诊断组(主要为失眠和尼古丁依赖)与较低IgG RBD水平相关(变化百分比=-21.53,95%CI -35.38至-4.71)。
- 使用第二代抗精神病药及近6个月使用多类精神药物者抗体水平较低。
核心结论
- 这些发现引发对心境障碍、当前或近期失眠和尼古丁依赖者以及使用多类精神药物者新冠疫苗效力及其他疫苗效力的担忧。
- 这些关联是否转化为突破性感染风险增加及SARS-CoV-2感染免疫介导的长期后遗症尚需进一步研究。
研究设计与样本
- 前瞻性人群研究,纳入西班牙加泰罗尼亚939名已接种新冠疫苗的成年人。
- 采用线性回归模型评估特定精神疾病及精神药物与抗体水平的关联,校正人口学、合并症和生活方式因素。
- 在247名基因分型亚组中评估精神疾病多基因风险评分(PRS)并进行两样本孟德尔随机化(MR)分析。
主要发现
- 心境障碍与较低的IgG RBD抗体相关(变化百分比=-26.37,95%CI -42.00至-6.54)。
- 焦虑障碍诊断与结局无关联。
- 其他诊断组(主要为失眠和尼古丁依赖)与较低IgG RBD水平相关(变化百分比=-21.53,95%CI -35.38至-4.71),近期发病(≤5年前)者抗体水平下降更明显。
- 使用第二代抗精神病药及近6个月使用多类精神药物者抗体水平较低。
- 基因分型人群中,精神分裂症遗传易感性较高(较高PRS)与较低IgG RBD水平相关(变化百分比=-35.49,95%CI -56.55至-4.23);MR分析显示重性抑郁遗传工具变量与较低IgG RBD和S水平存在因果关联。
关键数值与推荐
- 心境障碍与IgG RBD变化百分比=-26.37(95%CI -42.00至-6.54)。
- 其他诊断组与IgG RBD变化百分比=-21.53(95%CI -35.38至-4.71)。
- 精神分裂症较高PRS与IgG RBD变化百分比=-35.49(95%CI -56.55至-4.23)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些关联是否转化为突破性感染风险增加及SARS-CoV-2感染免疫介导的长期后遗症尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Background Mental illnesses have been overlooked as a potential factor influencing antibody responses to COVID-19 vaccine. Associations between mental disorders and antibody response might vary by specific disorders, depend on the long-term course of the illness and relate to psychotropic treatment. METHODS: The association between mental illness diagnoses (mood affective disorders, anxiety disorders, other) over ten years and psychotropic drug prescription based on electronic health records with antibody levels (IgG and IgA) post COVID-19 vaccination was assessed in 939 vaccinated adults from Catalonia, Spain. We employed linear regression models to assess associations between specific mental illnesses and psychotropic drugs with antibody levels, correcting for demographics, comorbidities and lifestyle factors. In a genotyped subset (n = 247) we assessed the effect of polygenic risk scores (PRS) for mental illnesses and performed a two-sample mendelian randomization (MR) analysis to examine causality between mental illness and antibody responses. RESULTS: Mood affective disorders were associated with lower IgG to receptor binding domain (RBD) [percentage change = -26.37 (95 % CI, -42.00, -6.54)]. Diagnosis of anxiety disorders was not associated with the outcome. The group of other diagnoses (mainly including insomnia and nicotine dependence) were associated with lower IgG RBD levels [percentage change: -21.53 (95 % CI, -35.38, -4.71)] and recent onset cases (≤5 years ago) showed greater decline in antibody levels. Participants on second-generation antipsychotics and multiple classes of psychotropic drugs in the last 6 months exhibited lower antibody levels. In the genotyped population, higher genetic liability (higher PRS) to schizophrenia was associated with lower IgG RBD levels [percentage change = -35.49 (95 % CI, -56.55, -4.23)]. MR analysis revealed a causal relationship between major depression genetic instrumental variables and lower IgG RBD and S levels. CONCLUSIONS: These findings raise concerns about the efficacy of COVID-19 vaccines and potentially of other vaccines as well, in individuals with mood affective disorders, current/recent insomnia and nicotine dependence and people on multiple psychotropic drugs. Whether these associations are translated into increased risk for breakthrough infections and immune mediated long-term sequels of the SARS-CoV-2 infection warrants further investigation.
引用
- Karachaliou M, Espinosa A, Farré X, et al. Mental illness and antibody responses after COVID-19 vaccination in a prospective population-based study in Catalonia. Vaccine. 2024. PMID: 39671776. doi:10.1016/j.vaccine.2024.126591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。